17,261 trials
Pediatric Recurrent Progressive Low-grade Gliomas · Pediatric Progressive Low-grade Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months — 67 percentage
HIV Infections
Primary: Occurrence of Vaccine-induced Systemic IgG Ab Binding to the 3 gp120 Env Proteins Contained in the Vaccine Regimen (ZM96, TV1.C, and 1086.C) in Group 1 and Group 2 — 29…
Metastatic Colorectal Cancer
Primary: Number of Participants With Dose-limiting Toxicities (DLT): Phase 1b — 0 Participants
Alpha1-Antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 3 Participants
Keratocystic Odontogenic Tumor
Primary: KCOT Volume (Greatest Dimension) — 3; 3.8; 0; 2.6 centimeter
Cancer of Rectum · Cancer of the Rectum · Neoplasm, Rectum
Primary: Complete Response Rate — 12 Participants
Organic Brain Syndrome, Nonpsychotic · Neurocognitive Disorders · Mental Disorder, Organic
Primary: The Number of Patients With Severe Adverse Events and Adverse Reactions — 0 Participants
Epilepsy · Dravet Syndrome · Lennox-Gastaut Syndrome
Primary: Percent Change From Baseline in Seizure Frequency Per 28 Days During the Maintenance Period — 3.11; -27.76 percent change — p=0.0007
Essential Tremor
Primary: Part A: Change From Baseline in Accelerometer-based Kinesia Kinetic Tremor Combined Score at Day 7 — 4.36; -0.69 score on a scale
Advanced Solid Tumors
Primary: Extent of Exposure to ARQ 197 in Participants Benefiting From Prior ARQ 197 Therapy — 125 Days
Alpha-1 Antitrypsin Deficiency · Emphysema · Chronic Obstructive Pulmonary Disease
Primary: Pulmonary Microvascular Blood Flow, Mean — 36.9; 35.1 mL blood/minute per 100mL lung — p=0.692
Congenital Adrenal Hyperplasia
Primary: Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101 — 2…
Cerebral Palsy
Primary: Change in Gross Motor Function Measure (GMFM-66) in Excess of Expected Change — 5.83; 4.27; 3.15 score on a scale
Meningitis, Meningococcal
Primary: Adjusted Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against N. Meningitidis Serogroup A for Each Vaccine Group and Between-group Ratios…
X-linked Hypophosphatemia
Primary: Safety and Efficacy of Repeated SC Injections of KRN23. — 21; 1; 1; 13 Participants